Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
Work
Year: 2023
Type: article
Abstract: Background AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)−specific neutralizing monoclonal antibodies (tixagevimab and cilgavimab). Metho... more
Authors Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, Rosalinda H. Arends, John Tillinghast +10 more
Institutions PAREXEL International (United Kingdom), AstraZeneca (United Kingdom), National Patient Safety Foundation, AstraZeneca (United States), NGM Biopharmaceuticals (United States)
Cites: 32
Cited by: 15
Related to: 10
FWCI: 4.611
Citation percentile (by year/subfield): 99.99
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,320
Funder AstraZeneca